Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus gasseri LA806
- Development stage
- Preclinical
- Lead developer
- PiLeJe
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactobacillus gasseri LA806** is a specific probiotic strain of the species *Lactobacillus gasseri*, evaluated primarily for its benefits in gastrointestinal health. Mechanistically, it supports intestinal barrier function by adhering strongly to intestinal epithelial cells and reinforcing the epithelial barrier, reducing hyperpermeability, and decreasing visceral hypersensitivity, as shown in preclinical models. In clinical studies, supplementation with this strain in patients with irritable bowel syndrome (IBS) led to significant improvements, including reduced abdominal pain, enhanced symptom severity scores, and improved quality of life. LA806 also demonstrated potential in reducing *Candida albicans* colonization and shaping a protective gut microbiota profile in animal models, through immunomodulation of macrophages and anti-inflammatory effects.
- Other names
- L. gasseri LA806
Beyond the preview
Go deeper on lactobacillus gasseri LA806.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus gasseri LA806.